Background
Compared to single-dose benzathine penicillin G (BPG), BPG plus a 7-day course of doxycycline (Doxy) was recently shown to enhance serologic response (seroresponse) for early syphilis in people with HIV (PWH). Ceftriaxone (CRO) is often added for concurrent gonorrhea, but the additional benefit of ceftriaxone to seroresponse of early syphilis remains uncertain. We aimed to compare serologic outcomes among PWH who received BPG alone, BPG+Doxy, and BPG+Doxy+CRO.
Methods
From Jan 2018 to Aug 2024, PWH with early syphilis who received single-dose BPG, BPG+Doxy, or BPG+Doxy+CRO (for concurrent gonorrhea) were retrospectively included. Exclusion criteria included baseline RPR <4, <2 follow-ups, or receipt of antibiotics active against T. pallidum (except Doxy or CRO). RPR titers were assessed every 3–6 months and seroresponse was defined as having a ≥4-fold decline at 12 months. Intention-to-treat (ITT) with last-observation-carried-forward (LOCF) and per-protocol (PP) analyses were conducted.
Results
A total of 1066 episodes in 760 PWH were included: 453 (42.5%) treated with BPG, 560 (52.5%) BPG+Doxy, and 53 (5.0%) BPG+Doxy+CRO. The median age was 37.7 years and baseline CD4 count 608 cells/mm³. At 12 months of treatment, the response rates in the ITT with LOCF analysis were 73.3% for BPG, 82.3% for BPG+Doxy, and 88.7% for BPG+Doxy+CRO (P <0.001) (Figure). The results of PP analysis were similar: 73.1%, 82.7%, and 89.8%, respectively (P<0.001). In multivariable analysis, higher baseline RPR titers (per 1-log₂, aOR 1.31; 95% CI 1.22–1.40) and Doxy-containing regimens (aOR 1.87; 95% CI 1.37–2.56) predicted seroresponse. The results were unchanged when repeat infections were excluded. Compared with BPG alone, BPG+Doxy was more likely to achieve a seroresponse (aOR, 1.87; 95% CI 1.37–2.56), and the same with BPG+Doxy+CRO (aOR 3.66; 95% CI 1.48–9.02). Compared with both BPG alone and BPG+Doxy, BPG+Doxy+CRO tended to enhance seroresponse (aOR 1.96; 95% CI 0.80–4.81), and, compared with BPG+Doxy, BPG+Doxy+CRO also tended to have a higher seroresponse (aOR 1.85; 95% CI 0.75–4.55), both of which did not achieve statistical significance likely related to the smaller sample size for PWH who received BPG+Doxy+CRO.
Conclusions
Doxy-containing regimens significantly improved 12-month seroresponse in PWH with early syphilis compared with BPG alone. Addition of CRO to BGP+Doxy may further enhance seroresponse, but the finding warrants confirmation in larger studies.
Table or Figure
